Coca-Cola remains resilient amid GLP-1 health trends and geopolitical risks, with proactive innovation and a diversified ...

Investing.com -- The European Medicines Agency’s (EMA) safety committee, PRAC, said Friday that it has concluded that ...

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The ...

Investing.com -- The European Medicines Agency ... is a "very rare side effect" of semaglutide medicines, including Ozempic, Rybelsus, and Wegovy. The medications, owned by Novo Nordisk ...

Ozempic-maker Novo Nordisk (NYSE:NVO) on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to ...

Eli Lilly is a pharma player, but it offers the growth of a tech stock thanks to its weight loss drugs portfolio. The weight ...

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic ... healthcare infrastructure investments and increasing awareness ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

surpassing LVMH on the back of soaring demand for Ozempic and Wegovy. Today, the Danish company has lost its grip on the anti-obesity market it carved out. The company has lost market share amid ...

Under Jorgensen’s leadership, Novo Nordisk became a world leader in the weight-loss drug market, with sky-rocketing sales of its Wegovy and Ozempic ... through its investment arm which owns ...

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic, Wegovy ... economies due to rising healthcare infrastructure investments and ...